Evaluation of a Clinical Support Website for the Management of Common Mental Health Conditions in Primary Care on Compliance With Benzodiazepine Prescribing Recommendations

NCT07379073 | Not Yet Recruiting

• 1 other identifier: Psycho-MG
• Study Type: interventional
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

This cluster-randomized study aims to evaluate the impact of a web-based clinical support tool on adherence to recommended maximum durations for benzodiazepine prescriptions among new users in primary care. General practitioners (GPs) participating in the study will have access to the website, which provides evidence-based algorithms for the management of common mental health conditions, including anxiety and sleep disorders. Prescription data and patient characteristics will be extracted from the French national health insurance database (DCIR). The primary outcome is the proportion of new benzodiazepine users whose prescriptions comply with recommended duration guidelines. Multilevel logistic regression models will assess the intervention effect, adjusting for patient- and GP-level factors.

Conditions

Benzodiazepine Use

Outcome Measures

Primary Outcomes (1)

• Compliance with recommended maximum duration of benzodiazepine prescriptions among new users

  Primary outcome measure: adherence to recommended prescription duration (yes/no) for benzodiazepines A patient is considered to have a prescription duration for benzodiazepines that is either adherent or non-adherent if they had no benzodiazepine exposure in the previous year and their duration of exposure during the first treatment episode: 1. is less than 12 weeks for anxiolytic benzodiazepines, 2. is less than 28 days for hypnotic benzodiazepines and related drugs, in accordance with current recommendations.

  12 months

Study Arms (2)

Experimental Group (trained on PsychoMG website)

EXPERIMENTAL

Training intervention on benzodiazepine prescribing with access to the PsychoMG website providing evidence-based clinical decision algorithms for anxiety and sleep disorder management.

Other: Training

Control Group

NO INTERVENTION

Training intervention on benzodiazepine prescribing without access to the PsychoMG website providing evidence-based clinical decision algorithms for anxiety and sleep disorder management.

Interventions

Training OTHER

Training intervention on benzodiazepine prescribing with access to the PsychoMG website providing evidence-based clinical decision algorithms for anxiety and sleep disorder management.

Experimental Group (trained on PsychoMG website)

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Being a general practitioner or a specialist in general medicine.
• Practicing in the Occitanie region.
• Working in private practice.
• Being registered under Sector 1 fee agreements.
• Providing informed consent to participate in the study.
• Having computer equipment in the medical office, available during consultation (desktop, laptop, tablet, or smartphone) with internet access.

You may not qualify if:

• \- Physicians who have been practicing for less than two years, as they are unlikely to have sufficient retrospective data on prescription reimbursements for their patients.

Sponsors & Collaborators

• MSPU de Pins-Justaret: lead

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 23, 2026
• First Posted: January 30, 2026
• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): October 1, 2028
• Last Updated: January 30, 2026

Record last verified: 2026-01